Clinical Trials · NCT07411560
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 100
- Start date
- Feb 2026
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea